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Long Term Outcomes of Surgical and Clinical Symptoms Following Minimally
Invasive Heller Myotomy: A Retrospective Clinical Database Review
Abstract
I
Introduction
Minimally invasive Heller myotomy rates have increased, but little evidence is available regarding long
term clinical and surgical outcomes. Our aim was to evaluate long term symptom improvement and
medication resolution for patients undergoing minimally invasive Heller myotomy.
Methods
A single-institution database was retrospectively reviewed for patients undergoing laparoscopic Heller
myotomy (LHM) or robotic Heller myotomy (RHM) during 2007-2018. Patients with primary HM followed
by a Dor fundoplication were included. Demographics and surgical data were analyzed. Esophageal
symptoms, testing, and medication use were collected preoperatively (pre-op), at 6-month (6-mo),
12-month (12-mo), and long-term (LT; 12-mo+) follow-up. Analysis was performed using SPSS v.23.0,
α=0.05.
Results
Eighty eight patients (RHM:N=66; LHM:N=22) were included. The majority were male (62.5%) and
Caucasian (89.8%), with a mean BMI of 27.3. Two patients had an intraoperative esophageal perforation,
each repaired with a non-eventful postoperative course. Mean follow-up time was 71 months overall, 75
months [11-171 months] and 40 months [6-158 months] for LHM and RHM, respectively. All patients
showed significant LT improvement of regurgitation, solid or liquid dysphagia, and Eckardt Score.
Postoperative proton pump inhibitor (PPI) use was significantly lower at LT (LHM:31.3%, RHM:19.4%)
compared to pre-op.
Conclusion
In this study, minimally invasive HM was a safe and effective treatment for achalasia symptom resolution
in the long term. Therefore, in our experience, minimally invasive HM is a safe therapy that helps maintain
symptom resolution.
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Abstract
Introduction: Minimally invasive Heller
myotomy (MIHM) rates have increased, but
little evidence is available regarding long term
(LT) clinical and surgical outcomes. Our aim
was to evaluate LT symptom improvement
and medication resolution for patients
undergoing MIHM.
Methods: A single-institution database
was retrospectively reviewed for patients
undergoing laparoscopic Heller myotomy
(LHM) or robotic Heller myotomy (RHM)
during 2007-2018. Patients with primary
HM followed by a Dor fundoplication were
included. Demographics, surgical data
and direct cost were analyzed. Esophageal
symptoms, testing, and medication use were
collected pre-operatively (pre-op), at 6-month
(6-mo), 12-month (12-mo), and LT (15-mo+)
follow-up. Analysis was performed using
SPSS v.23.0, α=0.05.
Results: Eighty eight patients (RHM:N=66;
LHM:N=22) were included. The majority
were male (62.5%) and Caucasian (89.8%),
with a mean BMI of 27.3. Two patients had
an intraoperative esophageal perforation, each
repaired with a non-eventful post-operative
course. Mean follow-up time was 71 months
overall, 75 months [11-171 months] and 40
months [6-158 months] for LHM and RHM,
respectively. All patients showed significant
LT improvement of regurgitation, solid or
liquid dysphagia, and Eckardt Score. Postoperative proton pump inhibitor (PPI) use
was significantly lower at LT (LHM:31.3%,
RHM:19.4%) compared to pre-op.
Conclusion: In this study, MIHM was a safe
and effective treatment for achalasia symptom
resolution in the LT. Therefore, in our
experience, MIHM is a safe therapy that helps
maintain symptom resolution.

Introduction
Achalasia is a functional disorder of the
esophageal body and lower esophageal
sphincter (LES), resulting in a wide array
of clinical symptoms.1,2 Although the cause
and contributing factors to the development
of achalasia are unknown, the resulting
symptoms are well detailed and include
dysphagia, regurgitation, chest pain and
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cough. Several treatment options are available
for achalasia, but Heller myotomy (HM) is
the accepted definitive surgical treatment, due
to its recognized long term (LT) benefits in
symptom resolution, medication resolution,
and quality of life improvements.3,4 Since
the first HM was performed over 100 years
ago, tremendous advancements have been
made in the procedure, including a transition
away from an open approach to a minimally
invasive approach.5 Laparoscopic, and more
recently, robotic approaches are being adopted
because minimally invasive approaches
have been shown to decrease post-operative
complications and hospital length of stay.6
Minimally invasive surgery (MIS) has also
been shown to reduce operating time, reduce
re-bleeding, and decrease mortality in a
wide spectrum of specialties ranging from
neurosurgery to orthopaedics.7,8 In addition to
positive post-operative outcomes, dysphagia
rates, the leading sign of successful achalasia
treatment, have been shown to decrease
significantly after minimally invasive HM
(MIHM).9,10 This is an important finding
because progressive dysphagia leads to an
extremely poor quality of life in achalasia
patients if left untreated.11
Few studies have examined the benefits of
short-term and LT outcomes after laparoscopic
HM. Other authors have described benefits
in regards to lower rates of dysphagia and
heartburn, as well as improved swallowing
status.12,13 Still, fewer authors have looked
at robotic HM, with small cohorts ranging
from 14-56 patients.14,15 Therefore, despite
the data that exist on MIS benefits for
surgical procedures in general, there is a
lack of research substantiating feasibility
and LT results after both minimally invasive
Heller approaches, especially those with
a long follow-up time. Given the efficacy
of minimally invasive approaches in other
surgical fields, the aim of our study was to
evaluate short and LT symptom improvement
in patients who underwent MIHM.

Methods
A single institution database was
retrospectively reviewed for patients who
underwent either a robotic-assisted (RHM) or
laparoscopic Heller myotomy (LHM) between
2007 and 2018. Only adult patients who had

a diagnosis of achalasia and who underwent
primary HM followed by a Dor fundoplication
were included in this study. Three patients
underwent Nissen or Toupet fundoplication
and were excluded. The technique for HM
followed by Dor fundoplication comprises
of esophageal mobilization, release of
esophageal and gastric muscles fibers,
followed by a 180º anterior fundoplication.
The goal of the procedure is to facilitate LES
function and resolve achalasia.16 All surgeries
in this cohort were performed by the same
surgeon. Exclusion criteria included any
patient with other esophageal disease, such
as ineffective dysmotility or malignancy. A
diagnosis of achalasia was determined by
the Chicago Classification of esophageal
dysmotility standards, according to preoperative esophageal manometry testing.17
Demographics, such as gender, age, race,
body mass index (BMI), and smoking history
were collected. Patient health information
such as pre-operative esophageal symptoms
and testing, medication use, medical history,
and pre-operative comorbidities were
collected. Pre-operative esophageal testing
included esophagogastroduodenoscopy
(EGD), barium esophagram, manometry,
and pH testing. Esophageal symptoms were
analyzed using a validated esophageal score,18
and analysis was based on a composite
of mean scores. Surgical data comprised
surgical approach, operating time, blood loss,
intraoperative complications, and length of
stay. Post-operative complications, including
bleeding, ileus, and others were recorded.
Frequency of esophageal symptoms and
Eckardt score were collected using a validated
intra and extra esophageal symptom survey
pre-operatively (pre-op), and at 6-month (6mo), 12-month (12-mo), and LT (15+ months)
follow-up.
Data are presented as frequency for
categorical data, or as median or mean, for
continuous data according to normality.
Descriptive statistics were calculated for the
cohort, and comparisons were made using
t-tests or chi-square testing. The Sign test with
Bonferroni correction was used for additional
evaluation of symptoms improvement over
time compared to the baseline.19 Statistical
analysis was performed using SPSS v.25.0,
with α=0.05.
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Results
Eighty-eight patients underwent MIHM
followed by Dor fundoplication (RHM: N=66;
LHM: N=22) and met the inclusion criteria
for the study. The mean age was 53.1± 17.6
years and the mean BMI was 27.3 kg/m2.
Over half of patients were male (62.5%) and
Caucasian (89.8) (Table 1).
Table 2 shows intra-operative findings. All
hiatal hernias were repaired at the time of
surgery. A majority of patients had minimal
(<50mL) blood loss, and two patients had an
intra-operative complication. One patient in
each group had an intra-operative esophageal
perforation, which was repaired with a
non-eventful post-operative course. Postoperatively, length of stay was 2.14 ± 2.98
days overall, 1.87 ± 2.68 days for the robotic
approach, and 3.29 ± 3.9 for the laparoscopic
approach (p=0.203). Post-operative
complications occurred in four patients
overall, three with post-operative bleeding,
and one with post-operative ileus.

Eckardt score, as shown in Table 3. Table 4
demonstrates that symptom improvement
from baseline was significant in all symptoms,
with dramatic improvement in solid
dysphagia from baseline to LT (p<0.001).
Whether patients had laparoscopic or robotic
procedure, there were no differences in postoperative symptom scores.

at one year in 57 (65%) patients. Only three
patients were found to have objective GERD
diagnosed on post-operative UGI (5.2%),
whereas two patients had asymptomatic
recurrence of hiatal hernia. Use of postoperative PPI was also reduced to just 23% of
patients reporting PPI use, compared to 49%
at baseline (Table 5).

Mean LT follow-up time was 70 months ±
47.07. Follow up ranged from 11-171 months
in our cohort, with over a third of patients
having LT follow up data over 4 years (N=31).

Discussion

Dilation rates and recurrence of objective
GERD on upper gastrointestinal imaging
(UGI) were low in this cohort. Overall, 11
patients (12.5%) underwent post-operative
dilation, with three of them requiring multiple
procedures. Of the 11 patients dilated, two
had evidence of peptic stricture and responded
well to dilation and proton pump inhibitor
therapy. In the remaining nine, those with
dilated esophagus and angulation were
dilated with a 20mm balloon. No patients
had incomplete myotomy by manometry.
The earliest dilation happened at least seven
months after the surgery. UGI was performed

Overall symptom scores improved over
time, along with consistent improvement in

Table 1.

Demographics and pre-operative characteristics of patients undergoing minimally invasive Heller
myotomy. Descriptive statistics were calculated.
Overall
(n = 88)

RHM
(n = 66)

LHM
(n = 22)

N

%

N

%

N

%

Female

33

37.5

21

31.8

12

54.5

Male

55

62.5

45

68.2

10

45.5

Age – years (mean ± SD) 53.1 ± 17.6

51.4 ± 16.5

57.9 ± 19.8

Race
Caucasian

79

89.8

57

86.4

22

100

AA

3

3.4

3

4.5

0

0

Other

3

3.4

3

4.5

0

0

Pre-op BMI kg/m2

27.3 ± 4.6

Pre-op Eckardt Score

4.4 ± 2.5

Overall Follow-up (months) 70.1 ± 47.0

27.2 ± 4.6

28.5 ± 3.6

4.2 ± 2.8

4.4 ± 2.8

40 (6 -158)

75 (11 - 171)

RHM Robotic-assisted Heller Myotomy; LHM Laparoscopic Heller Myotomy; Pre-op preoperative;
AA African American

Table 2.

Intra-operative and peri-operative data on patients undergoing minimally invasive Heller myotomy.
Comparisons between groups were made using Chi-square analysis or Wilcoxon rank sum test.

Operative Hiatal Hernia Present
OR Time (min)
Blood Loss (ml)
LOS

Overall

RHM

LHM

p value

10 (11.4%)

7 (10.6%)

3 (13.6%)

0.521

190 ± 48.32

193.0 ± 48.4

175.2 ± 48.1

0.931

18.83 ± 22.30

15.6 ± 19.2

30.56 ± 29.7

0.203

2.14± 2.98

1.78 ± 2.5

3.29 ± 3.9

0.059

RHM Robotic-assisted Heller Myotomy; LHM Laparoscopic Heller Myotomy; LOS Length of Stay
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This study demonstrates the safety and
efficacy of MIHM. Our cohort of 88 patients
had a less than 4.5% complication rate,
with low rates of post-operative dilation.
A significant number of patients reported
improvement symptoms and heartburn scores
in the LT. Furthermore, over 50% of the
patients who reported pre-operative PPI use
were able to stop taking these medications
post-operatively.
The demographics of our cohort, including
race, gender, BMI, and age are similar to those
reported in the current HM literature.16,20,21
Conversely, our mean operative time of 190
minutes was slightly longer than that reported
in the literature (range:89-141 min).20,22 In
the current study, data were collected from
an academic medical center where residents
and students often play a role in the operation.
This may have contributed to the increased
length of OR time. Our average length of stay
was 2.14 days which falls within the expected
range of 1-4.3 days.19,22
The reported overall complication rates for
MIHM range from 1.8-6.3%.20,21 Esophageal
perforation is considered to be the most
prevalent and serious complication of MIHM.
In our study, only two patients (2.3%)
suffered esophageal perforations. In both of
these instances, perforations were repaired
intraoperatively and patients had an otherwise
unremarkable post-operative course. This
is within the reported perforation rates in
the literature ranging from 1-13% with one
study citing the esophageal perforation rate
as high as 33%.23 Mortality rates following
perforation have been reported to be as high
as 40%.24-27 The low rate of perforations
in our cohort, coupled with a significant
improvement in esophageal symptom scores,
supports that MIHM is a safe and efficacious
treatment for achalasia.
An important marker of success following
surgical treatment of achalasia is the
resolution of dysphagia and other esophageal
symptoms.9,10 Our study demonstrated that
MIHM provided resolution of esophageal
symptoms, including dysphagia, heartburn,
regurgitation, and cough, evaluated at LT. In a
LT study by Jeansonne et al., which evaluated
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esophageal symptoms, 95% of patients who
underwent MIHM demonstrated satisfaction
with their operation, over a follow-up period
of 10 years.12 Patients reported symptom
improvement in dysphagia and cough at shortand LT follow-up, when compared to baseline
(p<0.05). Improvement was not significant at
LT follow-up in other esophageal symptoms
such as heartburn, chest pain, regurgitation
or asthma (p>0.05). At 10-year follow-up,
62.5% of patients reported a lower symptom
score for dysphagia when compared to the
baseline. Whereas in our study, 98% of our
patients reported improved dysphagia rates at
LT, compared to baseline. Although Jeansonne
et al. indicated the effectiveness of MIHM
given the robust LT symptom resolution rates,
their study was limited by a sample size of
only 17 patients.12 The difference in sample
size between the two studies (N=88 vs. N=17)
may have contributed to the variable rates of
symptom resolution; however, both studies
ultimately corroborate the efficacy of MIHM.
In a study of over 200 patients,
Krishnamohan. et al., evaluated the severity
and frequency of dysphagia of patients after
MIHM using validated questionnaires.13 The
questionnaires were able to capture robust
data on dysphagia variability. The authors
stated a significant decrease in dysphagia postoperatively, with a third of patients (N=80)
reporting complete resolution of dysphagia at
6.4 years follow-up. Additionally, swallowing
difficulty was further classified into dysphagia
for liquids 31% (50/161) or solids 92.5%
(149/161). These results were much higher
than our LT dysphagia rates, which could be
due to the variation in surgery received by
the patients. In some cases, no fundoplication
was performed (N=23;4.6%). The surgeon’s
preference for the type of fundoplication also
varied between Toupet (N=268) and Dor
(N=209).
Our patients demonstrated no difference
between LHM and RHM in symptom
resolution. Similar results are seen when both
minimally invasive procedures, laparoscopy
and robotic-assisted, were evaluated
independently. A 2004 study by Ruurda et al,
sought to gather data on symptom resolution
for a small group of 14 patients undergoing
robotic HM (RHM). They found that 86%
(12/14) of patients reported dysphagia relief
after the procedure, whereas 14% (2/14)
reported heartburn, with a mean follow-up
time of only 11 months. Another study of 73
patients who underwent RHM, showed that
96% reported their swallowing status to be
good/excellent, with little information about
other symptom resolution.28
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Table 3.

Overall mean symptom scores over time for patients who underwent minimally invasive Heller
myotomy.
Pre-op

6-mo

12-mo

LT

Heartburn

1.631

0.360

0.412

0

Regurgitation

2.594

0.230

0.118

0

Solid Dysphagia

3.452

0.633

0.500

0.02

Liquid Dysphagia

2.833

0.298

0.194

0

Eckardt Score

4.398

0.760

0.560

0.315

Pre-op preoperative; 6-mo 6 months follow-up; 12-mo 12 months follow-up; LT Long-term follow-up

Table 4.

Symptom score improvement over time in patients who underwent minimally invasive Heller myotomy.
Repeated measures ANOVA was used to test for symptom score improvement.
6mo (n=43)

12mo (n=44)

LT (n=54)

Symptom

%Improved

p

%Improved

p

%Improved

p

Heartburn

54

<0.001

53

<0.001

61

<0.001

Regurgitation

78

<0.001

80

<0.001

79

<0.001

Solid Dysphagia

93

<0.001

77

<0.001

98

<0.001

Liquid Dysphagia

90

<0.001

89

<0.001

84

<0.001

Any Dysphagia

62

<0.001

70

<0.001

96

<0.001

Table 5.

Long term proton pump inhibitor resolution in patients who underwent minimally invasive Heller
myotomy.
Pre-op

6-mo

12-mo

LT

PPI use

N

%

N

%

N

%

N

%

Overall

36

49

10

18

1

2.8

11

23

LHM

11

61

3

19

0

0

5

31

RHM

25

45

7

18

1

3.8

6

19

Preop preoperative; 6-mo 6 months follow-up; 12-mo 12 months follow-up; LT Long-term follow-up,
RHM Robotic-assisted Heller Myotomy; LHM Laparoscopic Heller Myotomy

Although HM is the gold standard treatment
for achalasia, new alternatives have emerged
including per oral endoscopic myotomy
(POEM). POEM is a natural orifice
intervention for achalasia, showing mixed
results in the short and LT compared to
HM.29,30 POEM is praised for its short term
efficacy, low post-operative pain scores, and
quick return to normal function. However,
LT efficacy of POEM remains debated.31,32 A
systematic review comparing POEM to HM
in the LT, noted that POEM has a much higher
incidence of pathological reflux, which could
potentially lead to complications such as
Barrett’s esophagus.30 Additionally, one series
noted the high incidence of intraoperative
complications including burns and small
perforations (21%) and symptomatic
capnoperitoneum (11%).33 This study also
echoed the high incidence of GERD following
POEM, with a reported 38% of their patient

population experiencing GERD. Although our
focus was not to compare POEM to HM, our
objectively measured GERD rates were much
lower at 5.2% following HM, when compared
to POEM.
Freedom from medication after surgery is
an additional important marker of success
in these patients. We found that objectively
measured reflux in our patient population was
5.7% at 1-year follow-up. PPI use at 1-year
follow-up was 2.8%, which is lower than
our UGI objectively measured GERD. At LT
follow-up 23% of our cohort reported PPI use.
This is much lower than reported rates in the
literature. Medication use rates after MIHM
has been reported to range from 25% to 66%
of patients taking anti-reflux medications
such as antacids, Histamine H2-receptor
antagonists (H2 blockers), calcium channel
blockers (CCB) or PPI post-operatively.34,35
Original Reports 22

A study of over 500 patients who underwent
MIHM showed 66% of patients (159/241)
were taking antacids, Histamine 2 blockers,
or PPI at LT follow-up (mean 6.4 years).13
While these authors used objective testing
in the form of pre-operative manometry to
diagnose achalasia, there was no objective
testing routinely obtained post-operatively. In
a different cohort, 25% of patients had severe
enough reflux symptoms post operatively to
require PPI therapy.35
Perry et al., evaluated the difference in
medication use between MIS approaches,
and found 56% of robotic patients and 80%
of laparoscopic patients required medication
for reflux at LT follow-up.14 While they cite
their PPI use as “very high,” the authors point
to a need for objective testing to determine
if the symptoms are truly a result of acid
reflux. Others have reported more descriptive
breakdowns, with 41%, 7% and 2% of
patients post-operatively taking PPIs, CCBs,
and Nitroglycerine, respectively.36 In our

patient cohort, only 23% of patients reported
taking PPIs at LT follow-up, versus 49% at
pre-op.
Our study has several limitations, including
its retrospective nature and the limited sample
size. However, this is one of the largest
studies to our knowledge and with an overall
response rate of 61% (54/88) at LT followup, we found consistent data collection in
our patient population. In order to limit the
effects of recall bias, we routinely collected
symptom scores at 3-, 6- and 12-months
post-operatively and established these time
points as our standard of care. The survey we
provided pre- and post-operatively at intervals
of 3-, 6-, 12-month, and LT, is a significant
assessment of a spectrum of esophageal and
extra-esophageal symptoms, and has been
validated in previous publications.19 Further,
the survey is a good measurement tool for
reported symptoms and is clinically relevant
to our patient population. Additionally,
we have pertinent information on reported

dysphagia, which is the most important
symptom relating to esophageal dysmotility,
and our survey gathers robust data on
dysphagia resolution. Due to the long duration
of follow-up in this study, patients who were
categorized as “lost to follow-up” were
elderly and died of unrelated causes. LT
objective measurement should be collected in
order to determine if the PPI use is related to
symptomatic GERD, or prescribed by another
specialty due to reasons unrelated to GERD.37
In conclusion, this study demonstrates
the efficacy of MIHM in symptom relief
and medication freedom for patients with
achalasia. MIHM provides significant
symptom relief in both the short-term and
LT along with significant reduction in use of
anti-reflux medications. Given the feasibility
and safety of both laparoscopy and the robotic
platform for a MIHM, either approach can
be used and should be based on surgeon
preference. 
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